Perspective 2020

Perinatal aspects on the covid-19 pandemic: a practical resource for perinatal-neonatal specialists

מאמר עמדה (באנגלית) שנכתב בראשית מגפת הקורונה ומסכם את הידע שהיה זמין אז על היבטים פרינטליים ונאונטליים של COVID-19, עם כלים מעשיים לרופאי פגים וילודים. המאמר משקף את מצב הידע במרץ 2020.

Authors:
Francis Mimouni, Satyan Lakshminrusimha, Stephen A. Pearlman, Tonse Raju, Patrick G. Gallagher, Joseph Mendlovic
Journal:
Journal of Perinatology (Springer Nature America, Inc.)
Dates:
Received 23 March 2020, accepted 25 March 2020
Affiliations:
Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel; Sackler School of Medicine, Tel Aviv, Israel
Abstract (English)

Background: Little is known about the perinatal aspects of COVID-19. Objective: To summarize available evidence and provide perinatologists/neonatologists with tools for managing their patients. Methods: Analysis of available literature on COVID-19 using Medline and Google scholar. Results: From scant data: vertical transmission from maternal infection during the third trimester probably does not occur or likely it occurs very rarely. Consequences of COVID-19 infection among women during early pregnancy remain unknown. We cannot conclude if pregnancy is a risk factor for more severe disease in women with COVID-19. Little is known about disease severity in neonates, and from very few samples, the presence of SARS-CoV-2 has not been documented in human milk. Links to websites of organizations with updated COVID-19 information are provided. Infographics summarize an approach to the pregnant woman or neonate with suspected or confirmed COVID-19. Conclusions: As the pandemic continues, more data will be available that could lead to changes in current knowledge and recommendations.

Literature review 2015

Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review

סקירת ספרות (באנגלית) של תופעות הלוואי שדווחו בעשר שנים של מחקרים על תרופות לטיפול בריפלוקס קיבתי-ושטי (GERD) בילדים: סותרי חומצה, חוסמי H2, מעכבי משאבת פרוטונים ותרופות פרוקינטיות.

Authors:
Shlomi Cohen, Mirjam Bueno de Mesquita, Francis B. Mimouni
Journal:
British Journal of Clinical Pharmacology (The British Pharmacological Society)
Dates:
Received 14 October 2014, accepted 26 February 2015, published online 5 March 2015
Affiliations:
The Pediatric Gastroenterology Unit and Department of Pediatrics, 'Dana-Dwek' Children's Hospital, Tel Aviv Medical Center; Sackler Faculty of Medicine, Tel Aviv University; Division of Neonatology, Shaare Zedek Medical Center, Jerusalem
Abstract (English)

Gastroesophageal reflux (GER) is commonly observed in children, particularly during the first year of life. Pharmacological therapy is mostly reserved for symptomatic infants diagnosed with GER disease (GERD), usually as defined in a recent consensus statement. The purpose of the present article was to review the reported adverse effects of pharmacological agents used in the treatment of paediatric GERD. We conducted this review using the electronic journal database Pubmed and Cochrane database systematic reviews using the latest 10-year period (1 January 2003 to 31 December 2012). Adverse effects have been reported in at least 23% of patients treated with histamine H2 receptor antagonists (H2RAs) and 34% of those treated with proton pump inhibitors (PPIs), and mostly include headaches, diarrhoea, nausea (H2RAs and PPIs) and constipation (PPIs). Acid suppression may place immune-deficient infants and children, or those with indwelling catheters, at risk for the development of lower respiratory tract infections and nosocomial sepsis. Prokinetic agents have many adverse effects, without major benefits to support their routine use.

המאמרים מוצגים כאן כשירות למטופלים ולקהילה הרפואית. זכויות היוצרים על הטקסטים שייכות למחברים ולמוציאים לאור של כתבי העת.

ייעוץ וחוות דעת

פרופסור מימוני מקבל ילדים ותינוקות לייעוץ ולחוות דעת במרפאתו הפרטית בצפון תל אביב. מוכר על ידי כל קופות החולים.

אבחון הפרעות קשב וריכוז לילדים מגיל 6 ולמבוגרים בתל אביב אצל פרופ׳ פרנסיס מימוני. תור בתוך כשבוע, בהתאם לזמינות. לפרטים נוספים